Pharma stock is engaged in manufacturing, distributing, and marketing pharmaceutical products catering to various medical areas jumped 12 percent in the day’s trade upon receiving approval to import for sale and distribution of drug used to treat cancer and tumors.
Price action
With a market capitalization of Rs. 18,728 Crores, the shares of Astrazeneca Pharma India Limited were trading at Rs. 7,490 per equity share, up 11 percent from its previous day’s close price of Rs. 6,746.45.
What Happened
AstraZeneca Pharma India Limited has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion (Imfinzi) from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India.
Durvalumab (IMFINZI) in combination with chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, is indicated for the treatment of patients with resectable (tumours 4 cm and/or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements
Also Read: Ambani group stock jumps 3% after receiving solar EPC orders worth ₹ 512 Cr
Durvalumab belonging to a class of drugs known as immune checkpoint inhibitors, is a monoclonal antibody used in cancer immunotherapy. Durvalumab targets and blocks the PD-L1 (programmed death-ligand 1) protein, allowing the immune system to detect and attack cancer cells more effectively.
About the Company
AstraZeneca Pharma India Limited is engaged in manufacturing, distributing, and marketing pharmaceutical products catering to various medical areas, including Cardiovascular, Renal, and Metabolic (CVRM) Diseases, Oncology, Respiratory, and Immunology.
It offers pharmaceutical medicines under notable brands such as Brilinta, Forxiga, Crestor, Tagrisso, Calquence, Zoladex, Symbicort, and many more
Financials & Ratios
Its revenue from operations grew by 31.15 percent from Rs. 295 Crores in Q1FY24 to Rs. 388 Crores in Q1FY25, accompanied by profits of Rs. 54 Crores to a loss of Rs. 12 Crores.
In terms of return ratios, it has reported a return on equity (ROE) of 22.9 percent and a return on capital employed (ROCE) of 31.1 percent. In terms of liquidity, it has reported a debt-to-equity ratio of 0.01.
Also Read: Alcohol stock with strong revenue growth guidance for FY25 to add to your watchlist
Written by: Bharath K.S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
